Literature DB >> 1347673

Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue.

T Kawamata1, H Akiyama, T Yamada, P L McGeer.   

Abstract

Expression of proteins associated with immune function was investigated immunohistochemically in postmortem brain and spinal cord of patients with amyotrophic lateral sclerosis (ALS). Reactive microglia/macrophages displaying high levels of leukocyte common antigen (LCA), the immunoglobulin receptor Fc gamma R1, lymphocyte function associated molecule-1 (LFA-1), the complement receptors CR3 and CR4, the class II major histocompatibility complex molecules HLA-DR, HLA-DP and HLA-DQ and common determinants of the class I HLA-A,B,C complex were abundant in affected areas in ALS. These areas included the primary motor cortex, motor nuclei of the brain stem, the anterior horn of the spinal cord, and the full extent of the corticospinal tract. A significant number of T lymphocytes of the helper/inducer (CD4+) and cytotoxic/suppressor (CD8+) subtypes were observed marginating along the walls of capillaries and venules and extending into the parenchyma of affected areas. Clusters of complement activated oligodendroglia as well as degenerating neurites positive for C3d and C4d were frequently detected in ALS-affected areas. These data provide evidence of immune-effector changes in ALS. They are consistent with an autoimmune or slow virus theory of the disorder, but may reflect only secondary changes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347673      PMCID: PMC1886170     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d.

Authors:  T Yamada; H Akiyama; P L McGeer
Journal:  Neurosci Lett       Date:  1990-05-04       Impact factor: 3.046

2.  Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease.

Authors:  I Tooyama; H Kimura; H Akiyama; P L McGeer
Journal:  Brain Res       Date:  1990-07-23       Impact factor: 3.252

Review 3.  Amyotrophic lateral sclerosis: an unconventional autoimmune disease?

Authors:  D B Drachman; R W Kuncl
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

4.  Monoclonal IgMs with anti-Gal(beta 1-3) GalNAc activity in lower motor neuron disease; identification of glycoprotein antigens in neural tissue and cross-reactivity with serum immunoglobulins.

Authors:  F P Thomas; A M Lee; S N Romas; N Latov
Journal:  J Neuroimmunol       Date:  1989-07       Impact factor: 3.478

5.  IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis.

Authors:  J I Engelhardt; S H Appel
Journal:  Arch Neurol       Date:  1990-11

6.  Immune system response in Alzheimer's disease.

Authors:  P L McGeer; H Akiyama; S Itagaki; E G McGeer
Journal:  Can J Neurol Sci       Date:  1989-11       Impact factor: 2.104

7.  Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies.

Authors:  N J Scolding; B P Morgan; A Houston; A K Campbell; C Linington; D A Compston
Journal:  J Neurol Sci       Date:  1989-02       Impact factor: 3.181

8.  Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes.

Authors:  D S Younger; L P Rowland; N Latov; W Sherman; M Pesce; D J Lange; W Trojaborg; J R Miller; R E Lovelace; A P Hays
Journal:  Neurology       Date:  1990-04       Impact factor: 9.910

9.  Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease.

Authors:  N Latov; A P Hays; P D Donofrio; J Liao; H Ito; S McGinnis; M Konstadoulakis; L Freddo; M E Shy; K Manoussos
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

Review 10.  Cytotoxicity mediated by human Fc receptors for IgG.

Authors:  M W Fanger; L Shen; R F Graziano; P M Guyre
Journal:  Immunol Today       Date:  1989-03
View more
  161 in total

Review 1.  Activated microglia: the silent executioner in neurodegenerative disease?

Authors:  S H Appel; E P Simpson
Journal:  Curr Neurol Neurosci Rep       Date:  2001-07       Impact factor: 5.081

2.  Amyotrophic Lateral Sclerosis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

3.  Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed.

Authors:  David B Wang; Robert D Dayton; Phillip P Henning; Cooper D Cain; Li Ru Zhao; Lisa M Schrott; Elysse A Orchard; David S Knight; Ronald L Klein
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

Review 4.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

Review 5.  Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.

Authors:  Elisabetta Vegeto; Valeria Benedusi; Adriana Maggi
Journal:  Front Neuroendocrinol       Date:  2008-04-29       Impact factor: 8.606

Review 6.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 7.  Glial cells in amyotrophic lateral sclerosis.

Authors:  T Philips; J D Rothstein
Journal:  Exp Neurol       Date:  2014-05-22       Impact factor: 5.330

8.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

Review 9.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

10.  Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity.

Authors:  James C Dodge; Amanda M Haidet; Wendy Yang; Marco A Passini; Mark Hester; Jennifer Clarke; Eric M Roskelley; Christopher M Treleaven; Liza Rizo; Heather Martin; Soo H Kim; Rita Kaspar; Tatyana V Taksir; Denise A Griffiths; Seng H Cheng; Lamya S Shihabuddin; Brian K Kaspar
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.